Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ.
Lemos C, et al. Among authors: guchelaar hj.
Pharmacogenomics. 2011 Feb;12(2):159-70. doi: 10.2217/pgs.10.172.
Pharmacogenomics. 2011.
PMID: 21332310
Free PMC article.